Shengdi Wu1,2, Cheng Yang3,4,5, Nuo Xu6, Lingyan Wang4,7, Yun Liu1, Jiyao Wang1,2, Xizhong Shen8,9,10,11. 1. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 2. Shanghai Institute of Liver Diseases, Shanghai, 200032, China. 3. Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 4. Shanghai Key Laboratory of Organ Transplantation, Shanghai, 200032, China. 5. Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 6. Department of Respiration, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 7. Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 8. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. xizhongshen@126.com. 9. Department of Internal Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. xizhongshen@126.com. 10. Shanghai Institute of Liver Diseases, Shanghai, 200032, China. xizhongshen@126.com. 11. Key Laboratory of Medical Molecule Virology, Ministry of Education and Health, Shanghai, 200032, China. xizhongshen@126.com.
Abstract
BACKGROUND: To investigate the protective effects of helix B surface peptide (HBSP) on acute liver injury induced by carbon tetrachloride (CCl4). METHODS: HBSP (8 nmol/kg) was intraperitoneally injected into C57 BL/6 mice 2 h after CCl4 administration. Serum and liver tissue samples were collected 24 h after injury. Liver function and histological injuries were evaluated. Inflammatory cell infiltration and cytokines were examined and hepatocytes apoptosis was measured. The human liver cell line LO2 and murine primary hepatocytes were stimulated by CCl4 with and without HBSP treatment and glutathione peroxidase activity, cell survival, and apoptosis were evaluated. In addition, we examined the PI3K/Akt/mTORC1 pathway to elucidate the mechanism underlying HBSP-mediated protection in acute liver injury. RESULTS: HBSP significantly decreased serum alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and pro-inflammatory cytokines in liver tissues after CCl4 injection compared with those in the control group. Immunohistochemical staining indicated that the number of CD3-, CD8-, and CD68-positive cells and the expression of cleaved caspase-3 were significantly decreased by HBSP treatment. Additionally, HBSP reduced apoptosis in vivo. In an in vitro study, the glutathione peroxidase activity and survival rate increased, while the total apoptotic rate was reduced in the HBSP-treated group compared with that in the control group after CCl4 treatment. HBSP activated the PI3K/Akt/mTORC1 pathway, which was confirmed by the PI3K inhibitor LY294002 both in vivo and in vitro. Furthermore, HBSP increased the survival of mice with acute liver injury, and this effect was abolished by LY294002. CONCLUSIONS: HBSP is a potential therapeutic agent against acute liver injury induced by CCl4.
BACKGROUND: To investigate the protective effects of helix B surface peptide (HBSP) on acute liver injury induced by carbon tetrachloride (CCl4). METHODS: HBSP (8 nmol/kg) was intraperitoneally injected into C57 BL/6 mice 2 h after CCl4 administration. Serum and liver tissue samples were collected 24 h after injury. Liver function and histological injuries were evaluated. Inflammatory cell infiltration and cytokines were examined and hepatocytes apoptosis was measured. The human liver cell line LO2 and murine primary hepatocytes were stimulated by CCl4 with and without HBSP treatment and glutathione peroxidase activity, cell survival, and apoptosis were evaluated. In addition, we examined the PI3K/Akt/mTORC1 pathway to elucidate the mechanism underlying HBSP-mediated protection in acute liver injury. RESULTS: HBSP significantly decreased serum alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and pro-inflammatory cytokines in liver tissues after CCl4 injection compared with those in the control group. Immunohistochemical staining indicated that the number of CD3-, CD8-, and CD68-positive cells and the expression of cleaved caspase-3 were significantly decreased by HBSP treatment. Additionally, HBSP reduced apoptosis in vivo. In an in vitro study, the glutathione peroxidase activity and survival rate increased, while the total apoptotic rate was reduced in the HBSP-treated group compared with that in the control group after CCl4 treatment. HBSP activated the PI3K/Akt/mTORC1 pathway, which was confirmed by the PI3K inhibitor LY294002 both in vivo and in vitro. Furthermore, HBSP increased the survival of mice with acute liver injury, and this effect was abolished by LY294002. CONCLUSIONS: HBSP is a potential therapeutic agent against acute liver injury induced by CCl4.
Entities:
Keywords:
Acute liver injury; Apoptosis; Helix B surface peptide; Inflammation
Authors: Hiroto Ueba; Michael Brines; Michael Yamin; Tomio Umemoto; Junya Ako; Shin-ichi Momomura; Anthony Cerami; Masanobu Kawakami Journal: Proc Natl Acad Sci U S A Date: 2010-07-26 Impact factor: 11.205
Authors: Michael Brines; Giovanni Grasso; Fabio Fiordaliso; Alessandra Sfacteria; Pietro Ghezzi; Maddalena Fratelli; Roberto Latini; Qiao-Wen Xie; John Smart; Chiao-Ju Su-Rick; Eileen Pobre; Deborah Diaz; Daniel Gomez; Carla Hand; Thomas Coleman; Anthony Cerami Journal: Proc Natl Acad Sci U S A Date: 2004-09-29 Impact factor: 11.205
Authors: M Collino; E Benetti; M Rogazzo; F Chiazza; R Mastrocola; D Nigro; J C Cutrin; M Aragno; R Fantozzi; M A Minetto; C Thiemermann Journal: Br J Pharmacol Date: 2014-11-24 Impact factor: 8.739
Authors: Tsutomu Fujii; Bryan C Fuchs; Suguru Yamada; Gregory Y Lauwers; Yakup Kulu; Jonathan M Goodwin; Michael Lanuti; Kenneth K Tanabe Journal: BMC Gastroenterol Date: 2010-07-09 Impact factor: 3.067
Authors: Cheng Yang; Charith U B Wijerathne; Guo-Wei Tu; Connie W H Woo; Yaw L Siow; Susara Madduma Hewage; Kathy K W Au-Yeung; Tongyu Zhu; Karmin O Journal: Front Immunol Date: 2021-06-04 Impact factor: 7.561